Rimantadine

Rimantadine

SCHEMBL1074987

CC(N)C12CC3CC(CC(C3)C1)C2.NC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

M

The experimentally established mechanism targets of Rimantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A2 O15244 2/20 0.82
SLC47A1 Q96FL8 2/20 0.82
MAPT P10636 1/20 0.78
GRIN1 Q05586 5/20 0.59
GRIN2A Q12879 5/20 0.59
LMNA P02545 4/20 0.59
GRIN2D O15399 4/20 0.59
GRIN3B O60391 4/20 0.59
GRIN2B Q13224 4/20 0.59
GRIN2C Q14957 4/20 0.59
GRIN3A Q8TCU5 4/20 0.59
SLC22A1 O15245 2/20 0.59
NFKB1 P19838 2/20 0.59
TSHR P16473 1/20 0.59
STAT6 P42226 1/20 0.59
SIGMAR1 Q99720 1/20 0.59
THRB P10828 2/20 0.56
PMP22 Q01453 2/20 0.56
POLB P06746 1/20 0.56
BLM P54132 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rimantadine SCHEMBL3719331 1.00 SLC22A2 (0.82) SLC22A2SLC47A1MAPTGRIN1GRIN2A
Rimantadine SCHEMBL2981 0.91 SLC22A2 (1.00) SLC22A2SLC47A1MAPTGRIN1GRIN2A
Rimantadine SCHEMBL15532385 0.91 SLC22A2 (1.00) SLC22A2SLC47A1MAPTGRIN1GRIN2A
Rimantadine SCHEMBL29908943 0.91 SLC22A2 (1.00) SLC22A2SLC47A1MAPTGRIN1GRIN2A
Rimantadine SCHEMBL20409367 0.91 SLC22A2 (1.00) SLC22A2SLC47A1MAPTGRIN1GRIN2A
Rimantadine SCHEMBL2982 0.91 SLC22A2 (1.00) SLC22A2SLC47A1MAPTGRIN1GRIN2A
Rimantadine SCHEMBL40906 0.88 MAPT (1.00) SLC22A2SLC47A1MAPTGRIN1GRIN2A
Rimantadine SCHEMBL4366035 0.88 MAPT (1.00) SLC22A2SLC47A1MAPTGRIN1GRIN2A
Rimantadine SCHEMBL28108817 0.88 MAPT (1.00) SLC22A2SLC47A1MAPTGRIN1GRIN2A
Rimantadine SCHEMBL14973619 0.86 SLC22A2 (0.90) SLC22A2SLC47A1MAPTGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230172904-A1 COMBINATION OF AN ANTIALLERGIC AGENT WITH MUSCARINIC ANTAGONIST AND/OR DOPAMINERGIC AGONIST FOR USE IN PREVENTING/STOPPING OF AXIAL MYOPIA IN HUMAN DAMBROSIO ENZO MARIA (IT) 2023-06-08 US disclosed
CN-110426462-B Method for detecting amantadine, rimantadine and memantine residues in animal derived food 佛山科学技术学院 2022-07-12 CN disclosed
WO-2021122957-A1 DENTAL ROOT CANAL FILLING COMPOSITION DENTSPLY DETREY GMBH (DE) 2021-06-24 WO disclosed
US-20200253951-A1 COMBINATION OF AN ANTIALLERGIC AGENT WITH MUSCARINIC ANTAGONIST AND/OR DOPAMINERGIC AGONIST FOR USE IN PREVENTING/STOPPING OF AXIAL MYOPIA IN HUMAN D'AMBROSIO ENZO MARIA (IT) 2020-08-13 US disclosed
CN-109580603-A A kind of detection and identification method of Ribavirin 广州安诺科技股份有限公司 2019-04-05 CN disclosed
EP-3416617-A1 COMBINATION OF AN ANTIALLERGIC AGENT WITH MUSCARINIC ANTAGONIST AND/OR DOPAMINERGIC AGONIST FOR USE IN PREVENTING/STOPPING OF AXIAL MYOPIA IN HUMAN D'Ambrosio, Enzo Maria (IT) 2018-12-26 EP disclosed
WO-2017140846-A1 COMBINATION OF AN ANTIALLERGIC AGENT WITH MUSCARINIC ANTAGONIST AND/OR DOPAMINERGIC AGONIST FOR USE IN PREVENTING/STOPPING OF AXIAL MYOPIA IN HUMAN D'AMBROSIO ENZO MARIA (IT) 2017-08-24 WO disclosed
WO-2011001258-A1 COMPOSITIONS, METHODS, AND KITS FOR TREATING VIRAL AND BACTERIAL INFECTIONS BY TOCOTRIENOLS, TOCOMONOENOLS, TOCODIENOLS, TOCOPHEROLS, AND THEIR DERIVATES EVITA LIFE SCIENCE PTE. LTD (SG) 2011-01-06 WO disclosed
CN-101862345-A The modified nucleosides that is used for the treatment of viral infection and abnormal cell proliferation PHARMASSET LTD 2010-10-20 CN disclosed
CN-1950069-A Anti-excititoxic sustained release intracular implants and related methods ALLERGAN INC (US) 2007-04-18 CN disclosed
CN-1646141-A Modified nucleosides for treating viral infections and abnormal cell proliferation PHARMASSET LTD (BB) 2005-07-27 CN disclosed